RxDoctor Payments Data

Jennifer Nayor, MD

Gastroenterology · Boston, MANPI 1790912731

Payments from drug & device makers

$2,470in general payments, 2019–2025

Across 108 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$704
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$550
  • Takeda Pharmaceuticals U.S.A., Inc.$346
  • Johnson & Johnson$259
  • Bristol Myers Squibb$211
  • Phathom Pharmaceuticals, Inc.$104
  • plus $296 from 6 others

What the payments were for

  • Food & beverage$2,45299%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,470 in reported general payments places this provider in the 55th percentile of 579 gastroenterology providers in Massachusetts.

See all gastroenterology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$99,807
Medicare patients
418
Services billed
687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab25$250,633
Humira PenAdalimumab15$91,835
RinvoqUpadacitinib11$72,302
LinzessLinaclotide48$49,960
VemlidyTenofovir Alafenamide12$16,228
Mesalamine12$10,152
Budesonide EcBudesonide23$6,973
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,917
Omeprazole177$2,788
Colestipol Hcl26$2,700
Scopolamine14$2,208
Pantoprazole Sodium109$1,510
Lansoprazole22$1,211
Balsalazide Disodium13$1,079
Sulfasalazine18$1,039

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$704$122,26259 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 579 gastroenterology providers in Massachusetts.

Other gastroenterology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →